Additionally, the company has completed COVID-19 vaccine first-dose clinics in all long-term care facilities that selected Walgreens as a vaccine provider.
In addition to supporting long-term care facilities, Walgreens began in-store vaccinations in 17 states and jurisdictions as part of the Federal Retail Pharmacy Program on Feb. 12.
The company administered nearly all 180,000 doses of the first weekly vaccine allotment within three days.
Beginning Feb. 25, Walgreens will receive a weekly allocation of more than 480,000 COVID-19 vaccine doses and support administration in the following states and jurisdictions, including: Arizona, Alaska, California, Chicago, Connecticut, Delaware, Georgia, Illinois, Kentucky, Maine, Maryland, Nevada, New Hampshire, New Mexico, New York, New York City, North Carolina, Ohio, Oregon, Puerto Rico, US Virgin Islands, Utah, Vermont, Virginia, West Virginia, Wisconsin and Wyoming.
Walgreens also continues to assist several states and jurisdictions with the administration of their COVID-19 vaccine allocations through in-store vaccinations or off-site clinics.
While supply remains limited, individuals eligible to receive the vaccine under the federal and state programs can schedule appointments by visiting Walgreens' website or through their state department of health website.
Walgreens is included in the Retail Pharmacy USA Division of retail and wholesale pharmacy operator Walgreens Boots Alliance, Inc. (NASDAQ: WBA).
It operates more than 9,000 retail locations across America, Puerto Rico and the US Virgin Islands.
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine